For this episode of Discovery Matters we are focusing on industry surveys and what they can tell us. This includes BioPlan and the Biopharma Resilience Index. Both huge reports providing insight into both the issues and opportunities facing the industry today.

Firman Ghouze, Cytiva’s Marketing Director in APAC, explains how the Biopharma Resilience Index came about, the industry issues it uncovers and potential solutions. We are also joined by Eric Langer, from BioPlan Associates, to discuss the BioPlan findings and how they echo many of the same themes. Finally, it was a delight to talk to Dr. Richard Wang, the founder and CEO of Neukio Biotherapeutics, who shares his insights as an industry leader.

This episode is an informative and accessible discussion on the state of the biopharma industry today. We discuss ways to tackle the most pressing challenges and how, if possible, we can best plan for the future.

Learn more about the Biopharma Resilience Index here.

Check out bioplanassociates.com.

Transcript

Keywords: industry, manufacturing, index, talent, biopharma, resilience, capacity, supply chain, talent pool, capital flows, pandemic, biopharma resilience index.